Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (323)
  2. Meeting Abstract (280)
  3. Review (19)
  4. Editorial (10)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (655)
  2. Center for Hematologic Malignancies (655)
  3. Department of Medicine (655)
  4. Hematologic Malignancies, Division of (655)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (118)
  3. Jae Park (81)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (274)
  2. Journal of Clinical Oncology (41)
  3. Blood Advances (27)
  4. Leukemia Research (27)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (25)

More Publications

Publishers
  1. American Society of Hematology (301)
  2. Elsevier Inc. (44)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (655)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
    Journal Article

    Wang, X. V.; Hanson, C. A.; Tschumper, R. C.; Lesnick, C. E.; Braggio, E.; Paietta, E. M.; O'Brien, S.; Barrientos, J. C.; Leis, J. F.; Zhang, C. C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?
    Editorial

    Bewersdorf, J. P.; Stone, R. M.; Tallman, M. S.; Stahl, M.
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Journal Article

    Bewersdorf, J. P.; Derkach, A.; Gowda, L.; Menghrajani, K.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation - A systematic review and meta-analysis
    Review

    Bewersdorf, J. P.; Allen, C.; Mirza, A. S.; Grimshaw, A. A.; Giri, S.; Podoltsev, N. A.; Gowda, L.; Cho, C.; Tallman, M. S.; Zeidan, A. M.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • CNS involvement in AML at diagnosis is rare and does not affect response or survival: Data from 11 ECOG-ACRIN trials
    Journal Article

    Ganzel, C.; Lee, J. W.; Fernandez, H. F.; Paietta, E. M.; Luger, S. M.; Lazarus, H. M.; Cripe, L. D.; Douer, D.; Wiernik, P. H.; Rowe, J. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis
    Meeting Abstract

    Bewersdorf, J. P.; Sheth, A.; Vetsa, S.; Grimshaw, A.; Giri, S.; Podoltsev, N. A.; Gowda, L.; Tamari, R.; Tallman, M. S.; Rampal, R.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis
    Review

    Bewersdorf, J. P.; Sheth, A. H.; Vetsa, S.; Grimshaw, A.; Giri, S.; Podoltsev, N. A.; Gowda, L.; Tamari, R.; Tallman, M. S.; Rampal, R. K.; more...
    Transplantation and Cellular Therapy (2021)

    Fulltext@MSK | Save
  • Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial
    Journal Article

    Luger, S. M.; Wang, V. X.; Rowe, J. M.; Litzow, M. R.; Paietta, E.; Ketterling, R. P.; Lazarus, H.; Rybka, W. B.; Craig, M. D.; Karp, J.; more...
    Leukemia Research (2021)

    Fulltext@MSK | Save
  • Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
    Review

    Kantarjian, H.; Short, N. J.; DiNardo, C.; Stein, E. M.; Daver, N.; Perl, A. E.; Wang, E. S.; Wei, A.; Tallman, M.
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Open-label phase II prospective, randomized, controlled study of romyelocel-L myeloid progenitor cells to reduce infection during induction chemotherapy for acute myeloid leukemia
    Journal Article

    Desai, P. M.; Brown, J.; Gill, S.; Solh, M. M.; Akard, L. P.; Hsu, J. W.; Ustun, C.; Andreadis, C.; Frankfurt, O.; Foran, J. M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save